specific, with negative immunofluorescence; liver and renal function normal, no cryoglobulins, serum concentration of C3 first noted to be low (40%; normal 70-120%). Aged 48 (1971) and aged 50 (1973) , the patient was admitted to Hammersmith Hospital for further investigations. Some evidence of keratoconjunctivitis sicca (conjunctival staining with rose bengal and abnormal Schirmer test). Investigations were normal except those pertaining to the complement system. In addition to the low C3 level, levels of Clq and C4 were low but levels of C5 and GBG (glycine rich /3-glycoprotein, a protein of the 'alternate pathway' of complement activation) were normal. Turnover studies using radiolabelled C3 and GBG showed hypercatabolism of these proteins. The level of Cl inhibitor was normal so the patient does not have hereditary angiocedema.
The patient's attacks continue, being little helped by antihistamines but apparently partially relieved by indomethacin.
Comment
This patient has peculiar skin lesions, and arthralgia with hypocomplementwmia. Studies of the patient's complement system suggest that it is being activated by the 'classical pathway', and the normal cause of this is the presence of circulating immune complexes. It seems likely that the skin lesions, arthralgias and complement activation in this patient are probably due to such circulating immune complexes, although an alternative explanation would be that an inherited or acquired defect of the complement system is resulting in its spontaneous activation and causing the clinical manifestations.
Four very similar cases have just been described (McDuffie et al. 1973) and it is of interest that, some years after the onset of the skin lesions, 2 of them developed membranoproliferative glomerulonephritis, which is another condition associated with evidence of complement activation. Two cases had had previous cobalt radiation and the growths had recurred, and fast neutron therapy was given to the previously irradiated area. Necrosis had been expected and had occurred but this was removable by surgical excision and the patients were alive and well two years after fast neutron therapy with no signs of tumour.
REFERENCE
Of the 20 patients who had been treated with fast neutrons, none had failed to respond and in 16 there was clinically complete regression of the tumour and none had recurred. Four patients died of metastases with regressing tumours. Ideally a controlled clinical trial should be conducted but the wide variety in the histology of sarcomas made comparison of similar tumours very difficult. Fast neutron therapy should, however, be considered before mutilating surgery was undertaken. 
